Company: CMND
Filing Date: 2025-12-05
Form Type: F-1/A
Source: 0001213900-25-118772
Chunk: 121

Company: Clearmind Medicine Inc.
Filing Date: 2025-12-05
Form: F-1/A
Chunk 121
---
 nine months ended July 31, 2025, amounted to $3,169,141 representing a decrease of $1,200,793, or 27%, compared to $4,369,934 for the nine months ended July 31, 2024. The decrease is as a result of a decrease in general and administrative expenses, a decrease in research and development expenses, an increase in the changes in fair value of derivative warrant liabilities and an increase in the interest income on deposits. 74 Year Ended October 31, 2024 Compared to Year Ended October 31, 2023 Research and development expenses Research and development expenses for the year ended October 31, 2024, amounted to $1,382,808, representing a decrease of $161,421, or 10.5%, compared to $1,544,229 for the year ended October 31, 2023. The decrease compared to the prior period mainly resulted from the expenses incurred to complete our pre-clinical program ahead of the commencement of our clinical trial. General and administrative expenses General and administrative expenses for the year ended October 31, 2024, amounted to $4,362,117, representing a decrease of $397,088, or 8.3%, compared to $4,759,205 for the year ended October 31, 2023. The decrease resulted primarily from a decrease in investor relations of $1,125,929, a decrease in professional fees of $212,170, offset by an increase in share-based compensation of $875,324. Net loss and comprehensive loss Net loss for the year ended October 31, 2024, amounted to $5,254,678 representing a decrease of $3,366,159, or 39.0%, compared to $8,620,837 for the year ended October 31, 2023. The decrease is as a result of a decrease in general and administrative expenses, a decrease in research and development expenses, an increase in the changes in fair value of derivative warrant liabilities of $2,897,788 and an increase in the interest income on deposits of $201,156. Income Taxes We have yet to generate taxable income in Canada. We anticipate that we will continue to generate tax losses for the foreseeable future and that we will be able to carry forward these tax losses indefinitely to future taxable years. Accordingly, we do not expect to pay taxes in Canada until we have taxable income after the full utilization of our carry forward